Moderna said it plans to cut R&D expense by $1.1 billion through portfolio prioritization and cost efficiencies, lowering it from 2024E $4.8 billion to $3.6 to 3.8 billion in 2027, and to focus on 10 product approvals through 2027.

1. 01

   Moderna said it plans to cut R&D expense by $1.1 billion through portfolio prioritization and cost efficiencies, lowering it from 2024E $4.8 billion to $3.6 to 3.8 billion in 2027, and to focus on 10 product approvals through 2027.

2. 02

   The company said it met all primary immunogenicity endpoints in its Phase 3 trial of its RSV vaccine for high-risk adults aged 18 to 59 and plans to submit a supplemental Biologics License Application for U.S. approval in 2024. It also said it expects to submit its flu/COVID combination vaccine and its next-generation COVID vaccine for approval in 2024.

3. 03

   Moderna said it expects 2025 revenue of $2.5 billion to $3.5 billion and year-end 2025 cash and investments of about $6 billion. It also said it expects to reach break-even on an operating cash cost basis in 2028 with $6 billion in revenue.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.